Clinical trials.gov says that for the "Phase 1b, a combination dose-escalation of IMU-201 (PD1-Vaxx) with atezolizumab and with or without chemotherapy, will enroll approximately 18-36 patients and establish the optimal combotherapy biological dose (cBOD)." There are 24 patients in the study, which is about in the middle of the number estimated. They are not recruiting now because the trial will end shortly. Not sure how you get "mothballed" out of this
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.2¢ |
Change
-0.002(14.3%) |
Mkt cap ! $93.33M | |||
| Open | High | Low | Value | Volume |
| 1.3¢ | 1.3¢ | 1.2¢ | $157.7K | 12.67M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 52 | 14777111 | 1.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.3¢ | 7404063 | 24 |
View Market Depth
| Last trade - 13.07pm 23/06/2025 (20 minute delay) ? |
| IMU (ASX) Chart |